Replies to post #25576 on Avid Bioservices Inc (CDMO)

[jazzbeerman]

Also -


as per RECIST:

"to be assigned a status of SD or PR, patients cannot have the appearance of any new lesions."

ALL PATIENTS in the Bavi trial are either PR or SD, (currently 50/50. Zero patients with PD).
NO PATIENTS in the Bavi trial have had any new lesions appear.
(Metastatic disease is what kills ya).

see Bavi's results in mice reducing breast cancer lung metastases, with this very combo - Bavi/Docetaxel -
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30171990


read why IMO Bavi should perform better in humans than in mice.
To data, it HAS performed better in humans, IMO this is why-
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30172392

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30172509



j

[JJPK]

Jazz, that clears it up for me. thanks
Joe K.